Global NIPT Market| BIS Research

A quick peek into the report

Report Description

Market Report Coverage - Global NIPT
Forecast Period : 2020-2030
CAGR by Revenue : 15.83%
CAGR by Volume : 20.58%

Market Report Coverage - Global NIPT
Base Year	2019	Market Size in 2019	$2,182.3 Million
CAGR During Forecast Period (by Revenue)	15.83%	Value Projection and Estimation by 2030	$10,818.4 Million
CAGR During Forecast Period (by Volume)	20.58%	Market Volume in 2019	3,142.14 Thousand Units
Forecast Period	2020-2030	Volume Projection and Estimation by 2030	23,583.25 Thousand Units
Research Hours	700	Number of Tables	16
Number of Pages	332	Number of Figures	232
Market Segmentation	• By Test – Panorama and Vistara; MaterniT GENOME, MaterniT 21 PLUS, informaSeq, Verifi and Verifi Plus Prenatal Tests; Harmony Test; NIFTY Test and NIFTY Test Pro; QNatal Advanced; PrenaTest, GeneSafe, and PrenatalSAFE; Bambni Test; IONA and Sage; and Others • By Platform– PCR, NGS, and Others • By Method – cfDNA and FCMB • By End User – Hospitals, Clinics, Diagnostic Labs, and Others • By Application – Trisomy Detection, Microdeletion Detection, Sex Chromosome Aneuploidy Detection, Others
Regional Segmentation	• North America – U.S., Canada • Europe – Germany, U.K., France, Italy, Switzerland, Spain, The Netherlands, Belgium, Russia, Poland, Denmark, Sweden, and Rest-of-Europe • Asia-Pacific – China, Australia, Japan, India, South Korea, Hong Kong, Malaysia, Indonesia, Vietnam, Thailand, Philippines, and Rest-of-Asia-Pacific • Latin America • Rest-of-the-World
Growth Drivers	• Increased emphasis on early detection and prevention • Availability of advanced screening technologies • Increasing consumer demand • Shifting of reimbursement policies toward more genetics coverage • High incidence rate of Down syndrome • Rising average maternal age • Increasing prevalence of genetic and congenital disorders
Market Challenges	• Stringent regulatory guidelines and ethical hurdles • Limitations of NIPT • Lack of awareness among consumers • Alternative screening and testing methods
Market Opportunities	• Capitalizing on the potential presented by the emerging markets of Asia • Availability of direct to consumer tests • Focus toward pre-implantation genetic diagnosis
Key Companies Profiled	Agilent Technologies, Inc., BGI, CENTOGENE N.V., Eurofins Scientific, F. Hoffmann-La Roche Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Annoroad Gene Technology, MedGenome Inc., Myriad Genetics, Inc., Next Biosciences, and Yourgene Health PLC.

Key Questions Answered in this Report:

What is the importance of NIPT, and what are the different NIPT products/services available in the market?

•   What is the importance of NIPT, and what are the different NIPT products/services available in the market? What are the different methods of NIPT, and what are the benefits and risks associated with it?
•   What are the major technological advancements witnessed by the global NIPT market in the past four years, and what is the future scope of the market? What are the key trends of the global NIPT market as per the year 2020, and how is the market evolving currently?
•   What were the market size and market volume of the global NIPT market in 2019, and what are the market size and market volume anticipated to be in 2030? What is the expected growth rate of the global NIPT market during the period between 2020 and 2030?
•   What is the market scenario and growth potential of different regions of the world, including North America, Europe, Asia-Pacific, and Rest-of-the-World?
•   What are the major drivers, challenges, and opportunities of the global NIPT market?
•   What are the major key players of the global NIPT market? How much market share does each of these players occupy in the market in 2019? Which companies are anticipated to be highly disruptive in the future, and why?
•   What is the regulatory scenario of the global NIPT market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of NIPT products?
•   What is the average NIPT cost in different countries? What is the reimbursement scenario of the global NIPT market, and what is the reimbursement rate in different countries of the world, including countries of North America, Latin America, Asia-Pacific, Europe, and Middle East and Africa?
•   What is the funding scenario of the market with respect to institutional and academic funding? What is the patent landscape of the market, and which companies stand out for registering the maximum number of patents?
•   What are the key developmental strategies implemented by the key players of the global NIPT market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
•   What are the different NIPT tests available in the market, and which test type dominates the market in 2019 and 2030 in terms of value and volume?
•   What is the global market size (by value and volume) of different types of products of the global NIPT market in 2019? What are the key trends of the market with respect to different kits, assays, and which product is expected to dominate the market in 2030?
•   What are the different technologies/platforms supported by NIPT products? Which technology type dominated the market in 2019 and is expected to dominate in 2030 (by value and volume)?
•   What are the different applications associated with NIPT? What was the contribution of each of the application areas in the global NIPT market for the time period between 2019 and 2030 (by value and volume)?
•   How is the global NIPT market segmented based on different methods (by value and volume)? Which method is currently leading the market, and why? Which method is expected to lead the market during the forecast?
•   What are the different end-users of the global NIPT market (by value and volume)? Which end-user type is the major contributor to the toral revenue in the market?
•   Which region is expected to contribute the highest sales in the global NIPT market between 2019 and 2030? What are the leading countries of different regions (by revenue and volume) that contribute significantly toward the growth of the NIPT market?

Market Overview

Our healthcare experts have found global NIPT market as one of the most rapidly evolving markets amongst the other prenatal testin

Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. Currently, NIPT is considered a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders. Moreover, advancements in genome sequencing technologies reduce turnaround time and the complexity of diagnosis with next generation sequencing (NGS). The NGS technology provides several opportunities to develop the non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders. The life science industry is witnessing significant growth of NIPT tests developed using the NGS technology. Several biotechnology companies are now indulging in the research and development of such NGS-based NIPT products. Furthermore, the advent of genome sequencing technologies in the life science industry has enabled the companies to detect the genetic diseases at an early stage and provide accurate results to remain competitive in the market.

Our healthcare experts have found global NIPT market as one of the most rapidly evolving markets amongst the other prenatal testing industries. The purpose of this study is to gain a holistic view of the NIPT market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the tests associated with the global NIPT market across different regions. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global NIPT market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

Within the research report, the market has been segmented into ‘tests,’ ‘methods,’ ‘platforms,’ ‘applications,’ ‘end-user’, and ‘regions.’. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The NIPT market is currently at a blooming phase, with the presence of various juggernauts such as F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc., BGI, Laboratory Corporation of America Holdings, and PerkinElmer Inc., as well as other medium and small-medium enterprises, that are offering wide range of NIPT products and services in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.

Download this TOC

Request a Sample

1.1 Inclusion and Exclusion

2.1   Overview: Report Scope
2.2   Segmentation of the Global NIPT Market
2.3   Assumptions and Limitations
2.4   Key Questions Answered in the Report
2.5   Base Year and Forecast Period

3.1   Overview: Report Methodology
3.2   Primary Data Sources
3.3   Secondary Data Sources
3.4   Market Estimation Model
3.5   Criteria for Company Profiling

4.1   Introduction
4.2   Factors Influencing the Adoption of NIPT
4.3   NIPT Approach
4.4   Different Methods of NIPT
4.5   Benefits and Risks Associated with NIPT
4.6   Chromosomal Aneuploidy
4.7   Features and Incidence Rate of Major Chromosomal Aneuploidies
4.8   Technological Advancements
4.9   World Economic Outlook of Prenatal Testing Market, 2019
4.10 Global Footprint

5.1   Overview
5.2   Impact Analysis
5.3   Market Drivers
5.3.1   Increased Emphasis on Early Detection and Prevention
5.3.2   Availability of Advanced Screening Technologies
5.3.3   Increasing Consumer Demand
5.3.4   Shifting of Reimbursement Policies Toward More Genetics Coverage
5.3.5   High Incidence Rate of Down’s Syndrome
5.3.6   Rising Average Maternal Age
5.3.7   Increasing Prevalence of Genetic and Congenital Disorders
5.4   Market Restraints
5.4.1   Stringent Regulatory Guidelines and Ethical Hurdles
5.4.2   Limitations of NIPT
5.4.3   Lack of Awareness Among Consumers
5.4.4   Alternative Screening and Testing Methods
5.5   Market Opportunities
5.5.1   Capitalizing on the Potential Presented by the Emerging Markets of Asia
5.5.2   Availability of Direct to Consumer Tests
5.5.3   Focus on Pre-Implantation Genetic Diagnosis

6.1   Regulatory Framework
6.1.1   Regulatory Scenario in the U.S.
6.1.2   Regulatory Scenario in Canada
6.1.3   Regulatory Scenario in the U.K.
6.1.4   Regulatory Scenario in Germany
6.1.5   Regulatory Scenario in France
6.1.6   Regulatory Scenario in Spain
6.1.7   Regulatory Scenario in Italy
6.1.8   Regulatory Scenario in the Netherlands
6.1.9   Regulatory Scenario in China
6.1.10   Regulatory Scenario in India
6.1.11   Regulatory Scenario in Australia
6.1.12   Regulatory Scenario in Japan
6.2   Clinical Laboratory Improvement Amendments (CLIA) Program
6.2.1   Regulatory Authorities Involved in CLIA Program
6.3   Cost and Access
6.4   Reimbursement Scenario
6.5   Funding Scenario
6.6   Supply Chain
6.7   Impact of COVID-19 Outbreak on the Global NIPT Market

7.1   Overview
7.2   Key Developments and Strategies
7.2.1   New Offerings
7.2.2   Partnerships and Alliances
7.2.3   Product Approval
7.2.4   Business Expansion
7.2.5   M&A Activities
7.2.6   Others
7.3   Market Share Analysis
7.4   Growth Share Analysis (Opportunity Mapping)
7.4.1   By Platform

8.1   Overview
8.2   Panorama and Vistara
8.3   MaterniT GENOME, MaterniT 21 PLUS, and informaSeq
8.4   Verifi and Verifi Plus Prenatal Tests
8.5   Harmony Test
8.6   NIFTY Test and NIFTY-Test Pro
8.7   QNatal Advanced
8.8   PrenaTest, GeneSafe, and PrenatalSAFE
8.9   Bambni Test
8.10 IONA and Sage
8.11   Others

9.1   Overview
9.2   cfDNA
9.3   FCMB

10.1   Overview
10.2   Next-Generation Sequencing
10.3   PCR
10.4   Others

11.1   Overview
11.2   Trisomy Detection
11.3   Microdeletion Detection
11.4   Sex Chromosome Aneuploidy Detection
11.5   Others

12.1   Overview
12.2   Hospitals
12.3   Clinics
12.4   Diagnostic Labs
12.5   Others

13.1   Overview
13.2   North America
13.2.1   Overview
13.2.2   U.S.
13.2.3   Canada
13.3   Europe
13.3.1   Overview
13.3.2   Germany
13.3.3   France
13.3.4   Italy
13.3.5   U.K.
13.3.6   Spain
13.3.7   Russia
13.3.8   Poland
13.3.9   Netherlands
13.3.10   Belgium
13.3.11   Switzerland
13.3.12   Denmark
13.3.13   Sweden
13.3.14   Rest-of-Europe
13.4   Asia-Pacific
13.4.1   Overview
13.4.2   China
13.4.3   Japan
13.4.4   India
13.4.5   Australia
13.4.6   South Korea
13.4.7   Hong Kong
13.4.8   Malaysia
13.4.9   Indonesia
13.4.10   Vietnam
13.4.11   Thailand
13.4.12   Philippines
13.4.13   Rest-of-APAC
13.5   Latin America
13.6   Rest-of-the-World

14.1   Overview
14.2   Agilent Technologies, Inc.
14.2.1   Company Overview
14.2.2   Role of Agilent Technologies, Inc. in the Global NIPT Market
14.2.3   Financials
14.2.4   Key Insights About Financial Health of the Company
14.2.5   SWOT Analysis
14.3   F. Hoffmann-La Roche Ltd
14.3.1   Company Overview
14.3.2   Role of F. Hoffmann-La Roche Ltd in the Global NIPT Market
14.3.3   Financials
14.3.4   Key Insights About Financial Health of the Company
14.3.5   SWOT Analysis
14.4   PerkinElmer, Inc.
14.4.1   Company Overview
14.4.2   Role of PerkinElmer, Inc. in the Global NIPT Market
14.4.3   Financials
14.4.4   Key Insights About Financial Health of the Company
14.4.5   SWOT Analysis
14.5   Quest Diagnostics Incorporated
14.5.1   Company Overview
14.5.2   Role of Quest Diagnostics Incorporated in the Global NIPT Market
14.5.3   Financials
14.5.4   SWOT Analysis
14.6   Illumina, Inc.
14.6.1   Company Overview
14.6.2   Role of Illumina, Inc. in the Global NIPT Market
14.6.3   Financials
14.6.4   Key Insights About Financial Health of the Company
14.6.5   SWOT Analysis
14.7   Myriad Genetics, Inc.
14.7.1   Company Overview
14.7.2   Role of Myriad Genetics, Inc. in the NIPT Market
14.7.3   Financials
14.7.4   Key Insights About Financial Health of the Company
14.7.5   SWOT Analysis
14.8   BGI
14.8.1   Company Overview
14.8.2   Role of BGI in the NIPT Market
14.8.3   SWOT Analysis
14.9   CENTOGENE N.V.
14.9.1   Company Overview
14.9.2   Role of CENTOGENE N.V. in the NIPT Market
14.9.3   Financials
14.9.4   Key Insights About Financial Health of the Company
14.9.5   SWOT Analysis
14.10 Laboratory Corporation of America Holdings
14.10.1   Company Overview
14.10.2   Role of Laboratory Corporation of America Holdings in the NIPT Market
14.10.3   Financials
14.10.4   SWOT Analysis
14.11   MedGenome Inc.
14.11.1   Company Overview
14.11.2   Role of MedGenome Inc. in the Global NIPT Market
14.11.3   SWOT Analysis
14.12   Annoroad Gene Technology
14.12.1   Company Overview
14.12.2   Role of Annoroad Gene Technology in the NIPT Market
14.12.3   SWOT Analysis
14.13   Natera, Inc.
14.13.1   Company Overview
14.13.2   Role of Natera, Inc. in the Global NIPT Market
14.13.3   Financials
14.13.4   Key Insights About Financial Health of the Company
14.13.5   SWOT Analysis
14.14   Yourgene Health PLC
14.14.1   Company Overview
14.14.2   Role of Yourgene Health PLC in the NIPT Market
14.14.3   Financials
14.14.4   SWOT Analysis
14.15   Next Biosciences
14.15.1   Company Overview
14.15.2   Role of Next Biosciences in the NIPT Market
14.15.3   SWOT Analysis
14.16   Eurofins Scientific
14.16.1   Company Overview
14.16.2   Role of Eurofins Scientific in the NIPT Market
14.16.3   Financials
14.16.4   SWOT Analysis

Table 1:   Leading Segments of the Global NIPT Market (by Revenue), 2019 and 2030
Table 4.1:   Major Chromosomal Aneuploidies
Table 4.2:   Technological Approach for NIPT
Table 5.1:   Impact Analysis of Market Drivers
Table 5.2:   Impact Analysis of Market Restraints
Table 5.3:   Risk of Chromosomal Abnormality w.r.t Maternal Age
Table 6.1:   List of Regulatory Authorities Involved in CLIA Program
Table 6.2:   Major Funding Activities (January 2017-June 2020)
Table 9.1:   Key Companies Offering cfDNA-Based NIPT Solution
Table 9.2:   Key Companies Offering FCMB-Based NIPT Solution
Table 10.1:   Key Companies Offering NGS-Based NIPT Solution
Table 10.2:   Key Companies Offering PCR-Based NIPT Solution
Table 10.3:   Key Companies Offering Other Platform-Based NIPT Solution
Table 11.1:   Key Companies Offering NIPT Solution for Trisomy Detection
Table 11.2:   Key Companies Offering NIPT Solution for Microdeletion Detection
Table 11.3:   Key Companies Offering NIPT Solution for SCA Detection

Figure 1:   Global NIPT Testing Market (by Region), by Revenue, 2019 and 2030
Figure 2:   Global NIPT Testing Market (by Region), by Volume, 2019 and 2030
Figure 3:   Impact of Market Drivers and Market Restraints
Figure 4:   Market Statistics
Figure 5:   Global NIPT Market Share (by Test), 2019-2030
Figure 6:   Global NIPT Market Share (by Method), 2019-2030
Figure 7:   Global NIPT Market Share (by Platform), 2019-2030
Figure 8:   Global NIPT Market Share (by Application), 2019-2030
Figure 9:   Global NIPT Market Share (by End User), 2019-2030
Figure 2.1:   Global NIPT Market Segmentation
Figure 3.1:   Global NIPT Market Methodology
Figure 3.2:   Primary Research Methodology
Figure 3.3:   Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4:   Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:   Prenatal Testing Timeline During Pregnancy
Figure 4.2:   Different Indications for NIPT
Figure 4.3:   NIPT Approach
Figure 4.4:   Benefits and Risks of NIPT
Figure 4.5:   Features of The Major Chromosome Aneuploidies
Figure 4.6:   Incidence Rate of The Major Chromosome Aneuploidies
Figure 4.7:   Ecosystem Players of Global Prenatal Testing Market
Figure 4.8:   Global NIPT Market, by Value
Figure 4.9:   Global NIPT Market, by Volume
Figure 5.1:   Births with Down’s Syndrome per 100 000 live births in European Region (2011-2018)
Figure 5.2:   Examples of Investment and Funding by Key Companies
Figure 6.1:   Classification of Tests in CLIA Program
Figure 6.2:   Cost Range of NIPT in Major Countries
Figure 6.3:   Reimbursement Scenario in Major Countries of the Global NIPT Market
Figure 6.4:   Supply Chain of Global NIPT Market
Figure 6.5:   The Growth Trend of the Global NIPT Market as was Expected in the Absence of COVID-19 and the Expected Growth Rate due to COVID-19 Outbreak, 2019-2030
Figure 7.1:   Competitive Landscape (January 2017-April 2020)
Figure 7.2:   Share of Key Developments and Strategies, January 2017-June 2020
Figure 7.3:   New Offerings (by Company), January 2017 and June 2020
Figure 7.4:   Partnerships and Alliances (by Company), January 2017 and June 2020
Figure 7.5:   Product Approvals (by Company), January 2017 and June 2020
Figure 7.6:   Business Expansion (by Company), January 2017 and June 2020
Figure 7.7:   M & A Activities (by Company), January 2017 and June 2020
Figure 7.8:   Market Share Analysis of Global NIPT Market, 2019
Figure 7.9:   Growth Share Matrix for NIPT Market (by Platform), 2018-2019
Figure 8.1:   Global NIPT Segmentation (by Test)
Figure 8.2:   Global NIPT Market (by Test) by Revenue, 2019-2030
Figure 8.3:   Global NIPT Market for Panorama and Vistara (by Revenue), 2019-2030
Figure 8.4:   Global NIPT Market for Panorama and Vistara (by Revenue), 2019-2030
Figure 8.5:   Global NIPT Market for Verifi and Verifi Plus Prenatal Tests (by Revenue), 2019-2030
Figure 8.6:   Global NIPT Market for Harmony Test, by Revenue, 2019-2030
Figure 8.7:   Global NIPT Market for NIFTY Test and NIFTY Test Pro (by Revenue), 2019-2030
Figure 8.8:   Global NIPT Market for QNatal Advanced (by Revenue), 2019-2030
Figure 8.9:   Global NIPT Market for PrenaTest, GeneSafe, and PrenatalSAFE (by Revenue), 2019-2030
Figure 8.10:   Global NIPT Market for Bambni Test (by Revenue), 2019-2030
Figure 8.11:   Global NIPT Market for IONA and Sage (by Revenue), 2019-2030
Figure 8.12:   Global NIPT Market for Other Tests (by Revenue), 2019-2030
Figure 9.1:   Global NIPT Segmentation (by Method)
Figure 9.2:   Global NIPT Market (by Method), by Revenue, 2019-2030
Figure 9.3:   Global NIPT Market (by Method), by Volume, 2019-2030
Figure 9.4:   Global NIPT Market for cfDNA (by Revenue), 2019-2030
Figure 9.5:   Global NIPT Market for cfDNA (by Volume), 2019-2030
Figure 9.6:   Global NIPT Market for FCMB (by Revenue), 2019-2030
Figure 9.7:   Global NIPT Market for FCMB (by Volume), 2019-2030
Figure 10.1:   Global NIPT Segmentation (by Platform)
Figure 10.2:   Global NIPT Market (by Platform), by Revenue, 2019-2030
Figure 10.3:   Global NIPT Market (by Platform), by Volume, 2019-2030
Figure 10.4:   Global NIPT Market for NGS (by Revenue), 2019-2030
Figure 10.5:   Global NIPT Market for NGS (by Volume), 2019-2030
Figure 10.6:   Global NIPT Market for PCR (by Revenue), 2019-2030
Figure 10.7:   Global NIPT Market for PCR (by Volume), 2019-2030
Figure 10.8:   Global NIPT Market for Other Platforms (by Revenue), 2019-2030
Figure 10.9:   Global NIPT Market for Other Platforms (by Volume), 2019-2030
Figure 11.1:   Global NIPT Segmentation (by Application)
Figure 11.2:   Global NIPT Market (by Application), by Revenue, 2019-2030
Figure 11.3:   Global NIPT Market (by Application), by Volume, 2019-2030
Figure 11.4:   Global NIPT Market for Trisomy Detection (by Revenue), 2019-2030
Figure 11.5:   Global NIPT Market for Trisomy Detection (by Volume), 2019-2030
Figure 11.6:   Global NIPT Market for Microdeletion Detection (by Revenue), 2019-2030
Figure 11.7:   Global NIPT Market for Microdeletion Detection (by Volume), 2019-2030
Figure 11.8:   Global NIPT Market for Sex Chromosome Aneuploidy Detection (by Revenue), 2019-2030
Figure 11.9:   Global NIPT Market for Sex Chromosome Aneuploidy Detection (by Volume), 2019-2030
Figure 11.1   Global NIPT Market for Others (by Revenue), 2019-2030
Figure 11.11:   Global NIPT Market for Others (by Volume), 2019-2030
Figure 12.1:   Global NIPT Segmentation (by End User)
Figure 12.2:   Global NIPT Market (by End User), by Revenue, 2019-2030
Figure 12.3:   Global NIPT Market (by End User), by Volume, 2019-2030
Figure 12.4:   Global NIPT Market for Hospitals (by Revenue), 2019-2030
Figure 12.5:   Global NIPT Market for Hospitals (by Volume), 2019-2030
Figure 12.6:   Global NIPT Market for Clinics (by Revenue), 2019-2030
Figure 12.7:   Global NIPT Market for Clinics (by Volume), 2019-2030
Figure 12.8:   Global NIPT Market for Diagnostic Labs (by Revenue), 2019-2030
Figure 12.9:   Global NIPT Market for Hospitals (by Volume), 2019-2030
Figure 12.10:   Global NIPT Market for Others (by Revenue), 2019-2030
Figure 12.11:   Global NIPT Market for Others (by Volume), 2019-2030
Figure 13.1:   Global NIPT Market (by Region), by Revenue, 2019 and 2030
Figure 13.2:   Global NIPT Market (by Region), 2019-2030
Figure 13.3:   Global NIPT Market (by Region), by Volume, 2019 and 2030
Figure 13.4:   Global NIPT Market (by Region), 2019-2030
Figure 13.5:   North America: NIPT Market (by Revenue), 2019-2030
Figure 13.6:   North America: NIPT Market (by Volume), 2019-2030
Figure 13.7:   North America: Market Dynamics
Figure 13.8:   North America: NIPT Market Share (by Country), by Revenue, 2019 and 2030
Figure 13.9:   North America: NIPT Market Share (by Country), by Volume, 2019 and 2030
Figure 13.10:   U.S. NIPT Market (by Revenue), 2019-2030
Figure 13.11:   U.S. NIPT Market (by Volume), 2019-2030
Figure 13.12:   Canada NIPT Market (by Revenue), 2019-2030
Figure 13.13:   Canada NIPT Market (by Volume), 2019-2030
Figure 13.14:   Europe: NIPT Market (by Revenue) and Volume, 2019-2030
Figure 13.15:   Europe NIPT Market (by Revenue and Volume), 2019-2030
Figure 13.16:   Europe Market Dynamics
Figure 13.17:   Europe: NIPT Market Share (by Country), by Revenue, 2019 and 2030
Figure 13.18:   Europe: NIPT Market Share (by Country), by Volume, 2019 and 2030
Figure 13.19:   Germany NIPT Market (by Revenue), 2019-2030
Figure 13.20:   Germany NIPT Market (by Volume), 2019-2030
Figure 13.21:   France NIPT Market (by Revenue and Volume), 2019-2030
Figure 13.22:   France NIPT Market (by Volume), 2019-2030
Figure 13.23:   Italy NIPT Market (by Revenue), 2019-2030
Figure 13.24:   Italy NIPT Market (by Volume), 2019-2030
Figure 13.25:   U.K. NIPT Market (by Revenue), 2019-2030
Figure 13.26:   U.K. NIPT Market (by Volume), 2019-2030
Figure 13.27:   Spain NIPT Market (by Revenue), 2019-2030
Figure 13.28:   Spain NIPT Market (by Volume), 2019-2030
Figure 13.29:   Russia NIPT Market (by Revenue), 2019-2030
Figure 13.30:   Russia NIPT Market (by Volume), 2019-2030
Figure 13.31:   Poland NIPT Market (by Revenue), 2019-2030
Figure 13.32:   Poland NIPT Market (by Volume), 2019-2030
Figure 13.33:   Netherlands NIPT Market (by Revenue), 2019-2030
Figure 13.34:   Netherlands NIPT Market (by Volume), 2019-2030
Figure 13.35:   Belgium NIPT Market (by Revenue), 2019-2030
Figure 13.36:   Belgium NIPT Market (by Volume), 2019-2030
Figure 13.37:   Switzerland NIPT Market (by Revenue), 2019-2030
Figure 13.38:   Switzerland NIPT Market (by Volume), 2019-2030
Figure 13.39:   Denmark NIPT Market (by Revenue), 2019-2030
Figure 13.40:   Denmark NIPT Market (by Volume), 2019-2030
Figure 13.41:   Sweden NIPT Market (by Revenue), 2019-2030
Figure 13.42:   Sweden NIPT Market (by Volume), 2019-2030
Figure 13.43:   Rest-of-Europe NIPT Market (by Revenue), 2019-2030
Figure 13.44:   Rest-of-Europe NIPT Market (by Volume), 2019-2030
Figure 13.45:   APAC NIPT Market (by Revenue), 2019-2030
Figure 13.46:   APAC: NIPT Market (by Volume), 2019-2030
Figure 13.47:   APAC Market Dynamics
Figure 13.48:   APAC NIPT Market Share (by Country), by Revenue, 2019 and 2030
Figure 13.49:   APAC NIPT Market Share (by Country), by Revenue and Volume, 2019 and 2030
Figure 13.50:   China NIPT Market (by Revenue), 2019-2030
Figure 13.51:   China NIPT Market (by Volume), 2019-2030
Figure 13.52:   Japan NIPT Market (by Revenue), 2019-2030
Figure 13.53:   Japan NIPT Market (by Volume), 2019-2030
Figure 13.54:   India NIPT Market (by Revenue), 2019-2030
Figure 13.55:   India NIPT Market (by Volume), 2019-2030
Figure 13.56:   Australia NIPT Market (by Revenue), 2019-2030
Figure 13.57:   Australia NIPT Market (by Volume), 2019-2030
Figure 13.58:   South Korea NIPT Market (by Revenue), 2019-2030
Figure 13.59:   South Korea NIPT Market (by Volume), 2019-2030
Figure 13.60:   Hong Kong NIPT Market (by Revenue), 2019-2030
Figure 13.61:   Hong Kong NIPT Market (by Volume), 2019-2030
Figure 13.62:   Malaysia NIPT Market (by Revenue), 2019-2030
Figure 13.63:   Malaysia NIPT Market (by Volume), 2019-2030
Figure 13.64:   Indonesia NIPT Market (by Revenue), 2019-2030
Figure 13.65:   Indonesia NIPT Market (by Volume), 2019-2030
Figure 13.66:   Vietnam NIPT Market (by Revenue), 2019-2030
Figure 13.67:   Vietnam NIPT Market (by Volume), 2019-2030
Figure 13.68:   Thailand NIPT Market (by Revenue), 2019-2030
Figure 13.69:   Thailand NIPT Market (by Volume), 2019-2030
Figure 13.70:   Philippines NIPT Market (by Revenue), 2019-2030
Figure 13.71:   Philippines NIPT Market (by Volume), 2019-2030
Figure 13.72:   Rest-of-APAC NIPT Market (by Revenue), 2019-2030
Figure 13.73:   Rest-of-APAC NIPT Market (by Volume), 2019-2030
Figure 13.74:   LATAM NIPT Market (by Revenue), 2019-2030
Figure 13.75:   LATAM NIPT Market (by Volume), 2019-2030
Figure 13.76:   R-o-W NIPT Market (by Revenue), 2019-2030
Figure 13.77:   R-o-W NIPT Market (by Volume), 2019-2030
Figure 14.1:   Shares of Key Company Profiles
Figure 14.2:   Agilent Technologies, Inc.: Product Portfolio for Global NIPT Market
Figure 14.3:   Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 14.4:   Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 14.5:   Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 14.6:   Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 14.7:   Agilent Technologies, Inc.: SWOT Analysis
Figure 14.8:   F. Hoffmann-La Roche Ltd: Product Portfolio for Global NIPT Market
Figure 14.9:   F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 14.10:   F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 14.11:   F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 14.12:   F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 14.13:   F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 14.14:   PerkinElmer, Inc.: Product Portfolio for Global NIPT Market
Figure 14.15:   PerkinElmer, Inc.: Overall Financials, 2017-2019
Figure 14.16:   PerkinElmer, Inc.: Revenue (by Segment), 2017-2019
Figure 14.17:   PerkinElmer, Inc.: Revenue (by Region), 2017-2019
Figure 14.18:   PerkinElmer, Inc.: R&D Expenditure, 2017-2019
Figure 14.19:   PerkinElmer, Inc.: SWOT Analysis
Figure 14.20:   Quest Diagnostics Incorporated’s Product Portfolio for Global NIPT Market
Figure 14.21:   Quest Diagnostics Incorporated -Overall Financials, 2017-2019
Figure 14.22:   Quest Diagnostics Incorporated, Revenue (by Segment), 2017-2019
Figure 14.23:   Quest Diagnostics Incorporated, SWOT Analysis
Figure 14.24:   Illumina, Inc.: Product Portfolio for Global NIPT Market
Figure 14.25:   Illumina, Inc.: Overall Financials, 2017-2019
Figure 14.26:   Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 14.27:   Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 14.28:   Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 14.29:   Illumina, Inc.: SWOT Analysis
Figure 14.30:   Myriad Genetics, Inc.: Product Portfolio for Global NIPT Market
Figure 14.31:   Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 14.32:   Myriad Genetics, Inc.: Revenue (by Product/Service), 2017-2019
Figure 14.33:   Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 14.34:   Myriad Genetics, Inc.: SWOT Analysis
Figure 14.35:   BGI: Product Portfolio for Global NIPT Market
Figure 14.36:   BGI: SWOT Analysis
Figure 14.37:   CENTOGENE N.V.: Product Portfolio for Global NIPT Market
Figure 14.38:   CENTOGENE N.V.: Overall Financials, 2017-2019
Figure 14.39:   CENTOGENE N.V.: Revenue (by Segment), 2017-2019
Figure 14.40:   CENTOGENE N.V.: Revenue (by Region), 2017-2019
Figure 14.41:   CENTOGENE N.V.: R&D Expenditure, 2017-2019
Figure 14.42:   CENTOGENE N.V.: SWOT Analysis
Figure 14.43:   Laboratory Corporation of America Holdings: Product Portfolio for Global NIPT Market
Figure 14.44:   Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 14.45:   Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 14.46:   Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 14.47:   Laboratory Corporation of America Holdings: SWOT Analysis
Figure 14.48:   MedGenome Inc.: Product Portfolio for Global NIPT Market
Figure 14.49:   MedGenome Inc.: SWOT Analysis
Figure 14.50:   Annoroad Gene Technology: Product Portfolio for Global NIPT Market
Figure 14.51:   Annoroad Gene Technology: SWOT Analysis
Figure 14.52:   Natera, Inc.: Product Portfolio for Global NIPT Market
Figure 14.53:   Natera, Inc.: Overall Financials, 2017-2019
Figure 14.54:   Natera, Inc.: Revenue (by Region), 2017-2019
Figure 14.55:   Natera, Inc.: R&D Expenditure, 2017-2019
Figure 14.56:   Natera, Inc.: SWOT Analysis
Figure 14.57:   Yourgene Health PLC: Product Portfolio for Global NIPT Market
Figure 14.58:   Yourgene Health PLC: Overall Financials, 2017-2019
Figure 14.59:   Yourgene Health PLC: Revenue (by Region), 2017-2019
Figure 14.60:   Yourgene Health PLC: SWOT Analysis
Figure 14.61:   Next Biosciences: Product Portfolio for Global NIPT Market
Figure 14.62:   Next Biosciences SWOT Analysis
Figure 14.63:   Eurofins Scientific: Product Portfolio for Global NIPT Market
Figure 14.64:   Eurofins Scientific Overall Financials, 2017-2019
Figure 14.65:   Eurofins Scientific Revenue (by Region), 2017-2019
Figure 14.66:   Eurofins Scientific: SWOT Analysis

Empty